Android app on Google Play

Bristol-Myers Squibb (BMY) Reports Waiting Period to Acquire Amylin Pharmaceuticals (AMLN) Expired

August 1, 2012 7:34 AM EDT Send to a Friend
Bristol-Myers Squibb (NYSE: BMY) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), for its tender offer for Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) (“Amylin”) has expired.

Bristol-Myers Squibb initiated on July 10, 2012, through its wholly-owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin for $31.00 per share.

The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which will expire at 5:00 PM (New York City time) on Tuesday, August 7, 2012, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.




You May Also Be Interested In


Related Categories

Mergers and Acquisitions

Add Your Comment